With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per ...

Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Wall Street saw slight gains on Thursday with positive earnings from major companies such as Eli Lilly and Tapestry. Despite ...

Wall Street was poised for a flat start as investors analyzed earnings from major companies like Honeywell and anticipated ...

Eli Lilly's (LLY) fourth quarter and full-year earnings mostly met Wall Street estimates but missed expectations for sales of its weight loss GLP-1 drugs Mounjaro and Zepbound.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY ... below the mean price target of $988.61. The Street-high price target of $1,190 implies a modest ...